Cost-effectiveness of pneumococcal vaccines among adults over 50 years old in low- and middle-income countries: a systematic review

References

• Said MA, Johnson HL, Nonyane BAS, et al. Estimating the Burden of Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis of Diagnostic Techniques. PLoS One. 2013. DOI:10.1371/journal.pone.0060273.
   Web of Science ®Google Scholar
• Berical AC, Harris D, Dela Cruz CS, et al. Pneumococcal vaccination strategies: an update and perspective. Ann Am Thorac Soc. 2016;13:933–944.
   PubMed Web of Science ®Google Scholar
• Dadonaite B, Roser M. Pneumonia [Internet]. Our World Data. 2019 [cited 2020 May 10]. Available from: https://ourworldindata.org/pneumonia#licence.
   Google Scholar
• Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012. DOI:10.1016/S0140-6736(12)61689-4.
   Web of Science ®Google Scholar
• CDC. Global Pneumococcal Disease and Vaccine [Internet]. 2018. Centers Dis. Control Prev. U.S. Dep. Heal. Hum. Serv
   Google Scholar
• Ordóñez JE, Orozco JJ. Cost-effectiveness analysis of the available pneumococcal conjugated vaccines for children under five years in Colombia. Cost Eff Resour Alloc. 2015. DOI:10.1186/s12962-015-0032-1
   PubMed Web of Science ®Google Scholar
• Mangen MJJ, Rozenbaum MH, Huijts SM, et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J. 2015. DOI:10.1183/13993003.00325-2015.
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH, Van Hoek AJ, Fleming D, et al. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ. 2012. DOI:10.1136/bmj.e6879.
   PubMed Web of Science ®Google Scholar
• Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004. DOI:10.1016/j.vaccine.2004.05.003
   PubMed Web of Science ®Google Scholar
• Mezones-Holguin E, Canelo-Aybar C, Clark AD, et al. Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru. Vaccine. 2015. DOI:10.1016/j.vaccine.2014.12.039.
   PubMed Web of Science ®Google Scholar
• Bogdan C, Falkenhorst G. Immunology and clinical efficacy of pneumococcal vaccination in elderly people. Internist Prax. 2018.
   Google Scholar
• Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003. DOI:10.1056/NEJMoa022678.
   Web of Science ®Google Scholar
• Berild JD, Winje BA, Vestrheim DF, et al. A systematic review of studies published between 2016 and 2019 on the effectiveness and efficacy of pneumococcal vaccination on pneumonia and invasive pneumococcal disease in an elderly population. Pathogens. 2020;9. DOI:10.3390/pathogens9040259.
   PubMed Web of Science ®Google Scholar
• Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015. DOI:10.1056/NEJMoa1408544.
   Web of Science ®Google Scholar
• Falkenhorst G, Remschmidt C, Harder T, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (ppv23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PLoS One. 2017. DOI:10.1371/journal.pone.0169368.
   PubMed Web of Science ®Google Scholar
• Moberley S, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database of Systematic Reviews;2013. DOI: 10.1002/14651858.CD000422.pub3
   PubMed Web of Science ®Google Scholar
• Porchia BR, Bonanni P, Bechini A, et al. Evaluating the costs and benefits of pneumococcal vaccination in adults. Expert Rev Vaccines. 2017;16:93–107.
   PubMed Web of Science ®Google Scholar
• Dirmesropian S, Wood JG, Macintyre CR, et al. A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly. Hum Vaccin Immunother. 2015;11:818–825.
   PubMed Web of Science ®Google Scholar
• Cafiero-Fonseca ET, Stawasz A, Johnson ST, et al. The full benefits of adult pneumococcal vaccination: A systematic review. PLoS One. 2017;12:e0186903.
   PubMed Web of Science ®Google Scholar
• Ogilvie I, El KA, Cui Y, et al. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: A systematic review of conclusions and assumptions. Vaccine. 2009;27:4891–4904.
   PubMed Web of Science ®Google Scholar
• Kraicer-Melamed H, O’Donnell S, Quach C. The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: A systematic review and meta-analysis. Vaccine. 2016. DOI:10.1016/j.vaccine.2016.02.024
   Web of Science ®Google Scholar
• Treskova M, Scholz SM, Kuhlmann A. Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: systematic Literature Review with Focus on Methods and Assumptions. Pharmacoeconomics. 2019;37:1093–1127.
   PubMed Web of Science ®Google Scholar
• Nishikawa AM, Sartori AMC, Mainardi GM, et al. Systematic review of economic evaluations of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in individuals 60 years of age or older. Vaccine. 2018;36:2510–2522.
   PubMed Web of Science ®Google Scholar
• Teresa Aguado M, Barratt J, Beard JR, et al. Report on WHO meeting on immunization in older adults: geneva, Switzerland, 22–23 March 2017. Vaccine. 2018;36:921–931.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009. DOI:10.1016/j.jclinepi.2009.06.005.
   Web of Science ®Google Scholar
• World Bank. World Bank Country and Lending Groups [Internet]. World Bank. 2020 [cited 2020 May 21]. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups.
   Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)-explanation and elaboration: A report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Heal. 2013;16(2):231–50. https://10.1016/j.jval.2013.02.002.PMID:23538175.
   Web of Science ®Google Scholar
• Akin L, Kaya M, Altinel S, et al. Cost of pneumococcal infections and cost-effectiveness analysis of pneumococcal vaccination in at risk adults and elderly in Turkey. Hum Vaccin. 2011. DOI:10.4161/hv.7.4.14188.
   PubMed Web of Science ®Google Scholar
• Castañeda-Orjuela C, Alvis-Guzmán N, Paternina ÁJ, et al. Cost-effectiveness of the introduction of the pneumococcal polysaccharide vaccine in elderly Colombian population. Vaccine. 2011;29:7644–7650.
   PubMed Web of Science ®Google Scholar
• Neto JT, De Araujo GTB, Gagliardi A, et al. Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil. Hum Vaccin. 2011. DOI:10.4161/hv.7.10.15987.
   PubMed Web of Science ®Google Scholar
• Ordóñez JE, Orozco JJ. Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia. BMC Infect Dis. 2014;14. DOI:10.1186/1471-2334-14-172.
   Web of Science ®Google Scholar
• De Soárez PC, Sartori AMC, Freitas AC, et al. Cost-effectiveness analysis of universal vaccination of adults aged 60 years with 23-valent pneumococcal polysaccharide vaccine versus current practice in Brazil. PLoS One. 2015;10:e0130217.
   PubMed Web of Science ®Google Scholar
• Zhao D, Gai Tobe R, Cui M, et al. Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China. Vaccine. 2016;34:6158–6165.
   Web of Science ®Google Scholar
• Sevilla JP, Stawasz A, Burnes D, et al. Indirect costs of adult pneumococcal disease and the productivity-based rate of return to the 13-valent pneumococcal conjugate vaccine for adults in Turkey. Hum Vaccines Immunother. 2020;16:1923–1936.
   PubMed Web of Science ®Google Scholar
• Nuñez SM, Mould-Quevedo JF, Gutierrez-Ardila MV, et al. PIN28 Cost Effectiveness Analysis of Vaccination With 13-Valent (PCV13) and 23-Valent (PPSV23) Pneumococcal Vaccines for Adults in Colombia. Value Heal. 2012. DOI:10.1016/j.jval.2012.03.1304.
   Web of Science ®Google Scholar
• Fujii RK, Mould JF, Presa J, et al. PIN76 Cost Effectiveness analysis of Vaccination with 13-Valent (PCV13) and 23-Valent (PPV23) Pneumococcal Vaccines for Senior Adults in Brazil. Value Heal. 2011;14(7):A279.
   Web of Science ®Google Scholar
• Cruz RB, Fernandes RA, Takemoto M, et al. PIN49 Economic Evaluation of 13-Valent Pneumococcal Vaccine in High Risk Elderly Population, From the Public Payer Perspective in Brazil. Value Heal. 2012;15(7): A394.
   Google Scholar
• Fujii RK, Roberts CS, Mould J, et al. PIN66 Cost Effectiveness Analysis of Vaccination With 13-Valent (PCV13) and 23-Valent (PPV23) Pneumococcal Vaccines for Senior Adults in São Paulo State, Brazil – public Perspective. Value Heal. 2012. DOI:10.1016/j.jval.2012.08.1133.
   Google Scholar
• Riofrio MFA, Vivero Altamirano RL, Mould Quevedo JF, et al. PIH17 Cost-Effectiveness Analysis of Anti-Pneumococcal Vaccination in High Risk and Adult Patients in Ecuador. Value Heal. 2012;15(4):A194.
   Google Scholar
• Molina JEO, Gutierrez-Ardila MV, Vargas Zea N. Cost Effectiveness Analysis Of Vaccination With 13-Valent (Pcv13) And 23-Valent (Ppsv23) Pneumococcal Vaccines For Adults In A Private Colombian Institution. Value Heal. 2013,16(3):A89–A90.
   Google Scholar
• Molina JEO, Gutierrez-Ardila MV, Vargas Zea N. Cost Effectiveness Analysis Of Vaccination With 13-Valent (Pcv13) And 23-Valent (Ppsv23) Pneumococcal Vaccines For Adults In Bogota, Colombia – public Scenario. Value Heal. 2013;16(3):A90.
   Google Scholar
• Yang H, Dasbach E, Guarin D, et al. Assessing the Public Health Impact and Cost Effectiveness of Pneumococcal Vaccines for Adults 65 Years of Age in Colombia. Value Heal. 2015. DOI:10.1016/j.jval.2015.09.015.
   Web of Science ®Google Scholar
• Baez-Revueltas F, Laredo F. Cost Effectiveness of Pcv13 Vs Ppsv23 For The Immunization of Adults Over 65 Years with Low or Moderate Risk of Pneumococcal Infection. Value in Health. 2017. DOI:10.1016/j.jval.2017.08.2914.
   Web of Science ®Google Scholar
• Jiang Y, Yang X, Petigara T, et al. A Cost-Effectiveness Analysis of Vaccinating The Elderly with The 23-Valent Pneumococcal Polysaccharide Vaccine (Ppv23) Compared To No Vaccination, The 13-Valent Pneumococcal Conjugate Vaccine (Pcv13), or Pcv13 Followed by Ppv23 in Brazil. Value Heal. 2017;20:A930.
   Web of Science ®Google Scholar
• Prieto E, Jiang Y, Yang X, et al. A cost-effectiveness analysis of vaccinating older adults with the 23-valent pneumococcal polysaccharide vaccine (PPV23) compared to no vaccination, the 13-valent pneumococcal conjugate vaccine (PCV13), or PCV13 followed by PPV23 in Colombia. Int J Infect Dis [Internet]. 2018;73:13.
   Web of Science ®Google Scholar
• Stoecker C, Kim L, Gierke R, et al. Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States. J Gen Intern Med. 2016. DOI:10.1007/s11606-016-3651-0.
   PubMed Web of Science ®Google Scholar
• Stoecker C, Kobayashi M, Matanock A, et al. Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program. Vaccine. 2020. DOI:10.1016/j.vaccine.2019.12.029.
   Web of Science ®Google Scholar
• Saokaew S, Rayanakorn A, Wu DBC, et al. Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review. Pharmacoeconomics. 2016;34:1211–1225.
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Almendares OM, Nanduri S, et al. 151. Evaluation of Pneumococcal Vaccine Effectiveness Against Invasive Pneumococcal Disease Among US Medicare Beneficiaries ≥65 Years Old. Open Forum Infect Dis [Internet]. 2018;5:S10–S11.
   Google Scholar
• Moberley SA, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2008;16:1–55.
   PubMed Web of Science ®Google Scholar
• Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: A comparison of meta-analyses. Eur J Epidemiol. 2004;19(4):353–363.
   Web of Science ®Google Scholar
• Conaty S, Watson L, Dinnes J, et al. The effectiveness of pneumococcal polysaccharide vaccines in adults: A systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine. 2004. DOI:10.1016/j.vaccine.2003.08.050.
   PubMed Web of Science ®Google Scholar